Our findings that CRTC1 may also play protective roles against dysregulation of cholesterol balance and insulin resistance further highlight the potential of CRTC1 as an alternative therapeutic target for NAFLD treatment. The gene discussed is CRTC1; the disease is metabolic dysfunction-associated steatotic liver disease.